Thursday, November 12, 2026

CBAK Energy Technology And 3 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

ViaNews Editorial Team

November 9, 2021

CBAK Energy Technology  And 3 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

(VIANEWS) - CBAK Energy Technology (CBAT), Entegris (ENTG), Armada Hoffler Properties (AHH) are the highest sales growth and return on equity stocks on this list.

Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. CBAK Energy Technology (CBAT)

20.5% sales growth and 47.94% return on equity

CBAK Energy Technology, Inc., through its subsidiaries, develops, manufactures, and sells lithium batteries in Mainland China, the United States, Europe, Taiwan, Israel, and internationally.

CBAK Energy Technology's sales growth this year is expected to be 22.3% and 14.9% for next year.

Year-on-year quarterly revenue growth grew by 27.4%, now sitting on 41.35M for the twelve trailing months.

Volume

Today's last reported volume for CBAK Energy Technology is 956783 which is 16.7% below its average volume of 1148720.

CBAK Energy Technology's sales growth is a negative 0% for the current quarter and 20.5% for the next. The company's growth estimates for the present quarter and the next is a negative 0% and negative 0%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 47.94%.

Volatility

CBAK Energy Technology's last day, last week, and last month's current volatility was 1.86%, 2.59%, and 2.79%, respectively.

CBAK Energy Technology's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 4.72% (day), 5.37% (last week), and 5.71% (last month), respectively.

CBAK Energy Technology's Stock Yearly Top and Bottom Value

CBAK Energy Technology's stock is valued at $2.15 at 05:22 EST, way under its 52-week high of $11.40 and above its 52-week low of $2.04.

CBAK Energy Technology's Moving Average

CBAK Energy Technology's value is below its 50-day moving average of $2.28 and way below its 200-day moving average of $3.50.

2. Entegris (ENTG)

15.4% sales growth and 24.71% return on equity

Entegris, Inc. develops, manufactures, and supplies microcontamination control products, specialty chemicals, and advanced materials handling solutions for manufacturing processes in the semiconductor and other high-technology industries in North America, Taiwan, South Korea, Japan, China, Europe, and Southeast Asia.

Entegris's sales growth this year is expected to be 21.9% and 11.1% for next year.

Year-on-year quarterly revenue growth grew by 27.4%, now sitting on 2.08B for the twelve trailing months.

Volume

Today's last reported volume for Entegris is 975994 which is 32.21% above its average volume of 738173.

Entegris's sales growth for the next quarter is 15.4%. The company's growth estimates for the present quarter and the next is 29.9% and 28.2%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 24.71%.

Volatility

Entegris's last day, last week, and last month's current volatility was 2.13%, 1.49%, and 1.59%, respectively.

Entegris's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 3.23% (day), 2.47% (last week), and 2.76% (last month), respectively.

Entegris's Stock Yearly Top and Bottom Value

Entegris's stock is valued at $145.34 at 05:22 EST, under its 52-week high of $149.40 and way higher than its 52-week low of $84.46.

Entegris's Moving Average

Entegris's value is way higher than its 50-day moving average of $130.82 and way higher than its 200-day moving average of $119.99.

3. Armada Hoffler Properties (AHH)

7.6% sales growth and 4.84% return on equity

Armada Hoffler Properties, Inc. (NYSE: AHH) is a vertically-integrated, self-managed real estate investment trust ("REIT") with four decades of experience developing, building, acquiring, and managing high-quality, institutional-grade office, retail, and multifamily properties located primarily in the Mid-Atlantic and Southeastern United States.

Armada Hoffler Properties's sales growth this year is expected to be 12.9% and 5.7% for next year.

Year-on-year quarterly revenue growth declined by 9.2%, now sitting on 375.38M for the twelve trailing months.

Volume

Today's last reported volume for Armada Hoffler Properties is 270460 which is 27.18% above its average volume of 212643.

Armada Hoffler Properties's sales growth is a negative 0% for the current quarter and 7.6% for the next. The company's growth estimates for the present quarter and the next is a negative 54.5% and 200%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 4.84%.

Volatility

Armada Hoffler Properties's last day, last week, and last month's current volatility was 1.70%, 2.44%, and 1.33%, respectively.

Armada Hoffler Properties's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 2.96% (day), 3.33% (last week), and 2.27% (last month), respectively.

Armada Hoffler Properties's Stock Yearly Top and Bottom Value

Armada Hoffler Properties's stock is valued at $15.29 at 05:22 EST, under its 52-week high of $15.64 and way higher than its 52-week low of $9.30.

Armada Hoffler Properties's Moving Average

Armada Hoffler Properties's worth is way higher than its 50-day moving average of $13.68 and way above its 200-day moving average of $13.42.

4. QAD (QADA)

6.1% sales growth and 6.06% return on equity

QAD Inc., together with its subsidiaries, provides cloud-based enterprise software solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America.

QAD's sales growth this year is expected to be 8.5% and 8.6% for next year.

Year-on-year quarterly revenue growth grew by 14.5%, now sitting on 327.45M for the twelve trailing months.

Volume

Today's last reported volume for QAD is 1563690 which is 598.7% above its average volume of 223798.

QAD's sales growth is a negative 0% for the ongoing quarter and 6.1% for the next. The company's growth estimates for the present quarter and the next is a negative 5.9% and negative -35.6%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.06%.

QAD's Stock Yearly Top and Bottom Value

QAD's stock is valued at $87.65 at 05:22 EST, under its 52-week high of $89.01 and way above its 52-week low of $45.08.

QAD's Moving Average

QAD's worth is above its 50-day moving average of $87.51 and higher than its 200-day moving average of $81.86.

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com